Inventiva halts Euronext Paris trading
Analysis based on 14 articles · First reported Jun 02, 2026 · Last updated Jun 02, 2026
The temporary trading halt of Inventiva's shares on Euronext Paris could create uncertainty for investors, potentially leading to volatility once trading resumes. The proposed financing transaction, once announced, will likely have a direct impact on Inventiva's stock price and market valuation.
Inventiva, a clinical-stage biopharmaceutical company, announced a temporary trading halt of its ordinary shares on Euronext Paris, effective from the market opening on June 2, 2026. This suspension was requested by Inventiva ahead of a proposed financing transaction, with details to be announced in a new communication. Trading on Euronext Paris is expected to resume on the same day at approximately 3:30 p.m. CEST, coinciding with the expected start of trading for Inventiva's ADSs on the Nasdaq Global Market.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard